drugset / Trial / NCT00619827

Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract

NCT00619827 ↗

Phase 1 Completed 89 enrolled Stallergenes Greer
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to assess the effect of grass pollen extract SLIT tablets on the Rhinoconjunctivitis Total Symptom Score (RTSS) of the six rhinoconjunctivitis symptoms in response to grass pollen challenge after one week, one, two and four months of treatment in patients suffering from Seasonal Allergic Rhinoconjunctivitis (SAR) due to grass pollen.

Timeline

Start
2007-09
Primary completion
2008-03
Completion
2008-03

Outcome

Met primary endpoint

registry analysis (superiority or other test); 300 IR vs Placebo; p = 0.0003; Mean Difference (Final Values) -1.97 (95% CI -2.99 to -0.94); ANCOVA NCT00619827 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject grass pollen allergen extract Unknown 300 unknown Other